Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
07/2008
07/31/2008US20080184386 Plant genome sequences and uses thereof
07/31/2008US20080184385 Use of GmRD22-like genes to protect against abiotic stress
07/31/2008US20080184381 Schizophrenia-related voltage-gated ion channel gene and protein
07/31/2008US20080182977 Molecules associated with cell proliferation
07/31/2008US20080182976 kit for detecting erythropoietin receptors which is capable of being activated comprising an antibody or fragment which activates formation or production of erythrocytes; treatment of anemia
07/31/2008US20080182974 Human cDNA clones comprising polynucleotides encoding polypeptides and methods of their use
07/31/2008US20080182973 Enhance cellular uptake of uncharged antisense oligonucleotide; forming a conjugate and arginine-rich peptide; oligonucleotide includes a string of contiguous guanine bases; substitute inosine base to limit the number of contiguous guanine bases to three; cancer, polycystic kidney disease, restenosis
07/31/2008US20080182972 D-amino acid dehydrogenase and method of making D-amino acids
07/31/2008US20080182971 1-pyreneacetic acid, 1-pyrenemethylamine, 5(6)-carboxyfluorescein, EDTA, cyclam tetraacetic acid, lauric acid, cholesterol, D-biotin, carboxymethyl- beta -cyclodextrin, cysteine to form a peptide derivative; expose peptide derivative to silicon precursor; patterned by ink jet printing
07/31/2008US20080182970 Using cypin in assays, diagnostics and treatment of cognitive disorders
07/31/2008US20080182807 gene therapy against tumors and cancer; expression vector includes insert into tumor an effective amount of polynucleotides encoding a functionally active p53, express p53 to first DNA damaging agent, contact tumor cell with first DNA damaging agent, and kill tumor cell
07/31/2008US20080182795 Specific antagonists for glucose-depenent insulinotropic polypeptide (GIP)
07/31/2008US20080182794 Methods for treating breast cancer using nrif3 related molecules
07/31/2008US20080182793 Polypeptide comprising oxidized lipid and/or carbohydrate binding activity for use as tool in diagnosis, prevention and treatment of thrombosis, atherosclerosis, inflammatory and bone disorders
07/31/2008US20080182790 Nucleic acid encoding protein which has autoinducer inactivation activity; increase disease resistance in plants and animals; capable of efficient inactivation of N-acyl homoserine lactone autoinducers
07/31/2008US20080182788 Compositions and Methods for Increasing Bone Mineralization
07/31/2008US20080182787 Protein isolated from plants (Moringa) or synthesized by recombinant DNA technology; enzyme inhibitors; prevention and treatment of metabolic, cardiovascular, and inflammatory diseases
07/31/2008US20080182785 Protracted Glp-1 Compounds
07/31/2008US20080182783 Pharmacokinetics; host cell
07/31/2008US20080182777 Regulation of cell migration and adhesion
07/31/2008US20080182331 Production of transgenic animals; targeted replacement of an endogenous gene; genetic trait expression; DNA gene inactivation construct
07/31/2008US20080182329 Methods and products related to metabolic interactions in disease
07/31/2008US20080182320 Two-step immunization procedure against chlamydia infection
07/31/2008US20080182316 Nucleic acids encoding opiate receptors
07/31/2008US20080182315 specified domain capable of independently functioning as a potential sensor and another domain exhibiting a phosphatise activity; capable of converting electrical signals to chemical signals
07/31/2008US20080182314 Neuronal serine threonine protein kinase
07/31/2008US20080182302 Open reading frames which encode polypeptides sufficient to direct the biosynthesis synthesis of a safracin molecule having improved properties and that could be used in the hemi-synthesis of new ecteinascidins compounds; combinatorial chemistry; antitumor agents; broad-spectrum antibiotics; bactericides
07/31/2008US20080182299 Polynucleotide variants of brain natriuretic peptides used as diagnostic markers for cardiovascular diseases including myocardial infarct, acute coronary syndrome, angina pectoris (stable and unstable), cardiomyopathy, myocarditis, congestive heart failure; kits; monitoring disease progression , relapse
07/31/2008US20080182294 Recombinant clostridial neurotoxins (botulinum) having functional binding, translocation, and therapeutic domains; also an amino acid sequence susceptible to specific cleavage by proteases in vitro following expression as a single chain; inserts; therapeutic agents, transporter molecules; drug delivery
07/31/2008US20080182284 Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes
07/31/2008US20080182283 Inhibitors of human plasmin derived from the kunitz domains
07/31/2008US20080182279 Bacillus crystal protein having improved insecticidal activity; transgenic plant; polynucleotide segment having a sequence region that encodes an insecticidal hybrid delta-endotoxin protein; immunoassay
07/31/2008US20080182275 Secreted and transmembrane polypeptides and nucleic acids encoding the same
07/31/2008US20080182270 Combinatorial artificial receptors including peptide building blocks
07/31/2008US20080182268 Schizophrenia associated genes, proteins and biallelic markers
07/31/2008US20080182267 Method for predicting a drug transport capability by abcg2 polymorphisms
07/31/2008US20080182266 Trp8, a transient receptor potential channel expressed in taste receptor cells
07/31/2008US20080182242 Dominant-negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into mammalian cells new cell lines with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation
07/31/2008US20080182236 Within human chromosome 7p15-p14; GPRA polypeptides, nucleic acids, host cells, primers and probes; transgenic animal models; anticarcinogenic agents; chronic obstructive pulmonary disorder; diagnosis; analyzing allelic variation in the locus and GPRA gene
07/31/2008US20080182002 Processes for Removing Bitter Components from Soy Protein Isolates
07/31/2008US20080181935 Base-treated, detergent-treated telopeptide collagen and a plurality of stem cells; kit for augmenting, bulking or replacing tissue of a mammal
07/31/2008US20080181918 Immunogens; vaccines; fusion proteins
07/31/2008US20080181915 Cd40 ligand adjuvant for respiratory syncytial virus
07/31/2008US20080181914 an inactivated, disrupted influenza virus preparation of a hemagglutinin antigen stabilised by alpha-tocopherol succinate in the absence or at low levels of thiomersal; hemagglutinin detectable by a single radial immunoassay (SRID); mercury-free preservative; administering by any route
07/31/2008US20080181912 Nucleotide sequences encoding vector expressing in vivo at least one immunogen of pathogen and an in vivo expression vector comprising a polynucleotide encoding a polypeptide having an insulin-like growth factor IGF-1 activity; immunogenic composition
07/31/2008US20080181908 Genes and proteins, and their use
07/31/2008US20080181907 Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia
07/31/2008US20080181906 For inducing neutralizing antibodies against HIV; hairpin motif; HIV gp120; hydrogen bonding
07/31/2008US20080181904 Contains collagen-like domain and Clq domain; idiotypic antibodies; humanizing; biosynthesis
07/31/2008US20080181902 Mutant protofibril for active immunisation; synuclein genes, proteins; Parkinson's disease; dementia
07/31/2008US20080181901 Protein modulator of the plasma membrane Na,K-ATPase
07/31/2008US20080181898 Wise/sost nucleic acid sequences and amino acid sequences
07/31/2008US20080181897 Which specifically bind to or interact with human G-CSF receptor and dimerize the receptor or activate phosphorylation of kinases associated with the receptor to stimulate cell proliferation and differentiation
07/31/2008US20080181895 SP16 protein
07/31/2008US20080181885 202P5A5 gene or fragment or its encoded protein, or variants , or a fragment, used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 202P5A5 be used in active or passive immunization; gene therapy, immunotherapy; anticarcinogenic agent biodrug for pancreatic cancer
07/31/2008US20080181883 Purified Antigen for Alzheimer's Disease and Methods of Obtaining and Using Same
07/31/2008US20080181871 Focal calcium channel modulation
07/31/2008US20080181864 Reducing mitochondrial membrane potential in mammalian cell by administering an major histocompatibility complex (MHC) class II HLA-DR (human leukocyte antigen) ligand; control disease by manipulating mitochondrial metabolism; drug screening antitumor drug; treating human breast cancer
07/31/2008US20080181849 Methods, kits and compositions comprising crotamine
07/31/2008DE102007005190A1 Peptide useful for specifically killing cells comprises a sequence capable of coupling to a specific-binding molecule, an oligomerization sequence and a sequence for binding a cytotoxic component
07/31/2008DE102007004909A1 Use of pancreatic zymogen granule polypeptide GP2 as a medicament, especially for treating autoimmune diseases by plasmapheresis
07/31/2008DE102007004283A1 Magnetic resonance contrast agent comprises a polypeptide that binds to a biological structure in the body of a mammal and comprises an amino acid sequence of a bacterial iron-binding protein
07/31/2008CA2676481A1 Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens
07/31/2008CA2676098A1 Soluble fcgammaria and related methods
07/31/2008CA2675618A1 Factor h polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
07/31/2008CA2674213A1 Purification of fc-taci fusion proteins using the oilbody technology
07/31/2008CA2674021A1 Method for assaying antibodies in body fluids by immune reaction with glycoprotein 2 (gp2) from zymogenic granules of the pancreas for the differential diagnosis of inflammatory intestinal diseases and chronic pancreatitis
07/31/2008CA2666662A1 Methods to utilize invertebrate chemosensory proteins for industrial and commercial uses
07/30/2008EP1950306A1 Environmental stress tolerance genes
07/30/2008EP1950302A2 Streptococcus antigens
07/30/2008EP1950299A1 Mammalian receptor proteins; related reagents and methods
07/30/2008EP1950298A2 Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
07/30/2008EP1950292A1 Nato3, MARKER OF GROWING PROGENITOR CELL OF DOPAMINE-PRODUCING NEURON
07/30/2008EP1950226A2 Receptors for human interleukin-12
07/30/2008EP1950224A2 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
07/30/2008EP1950223A2 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
07/30/2008EP1950222A1 Method for proving antibodies in body fluids via an immune reaction with glycoprotein 2 (GP2) from zymogen granula of the pancreas for a differential diagnosis of inflammable intestinal illnesses and chronic pancreatitis
07/30/2008EP1950221A2 Genomic sequences of exported mycobacteria polypeptides, vectors containing them and applications to the diagnosis and prevention of tuberculosis
07/30/2008EP1949914A1 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
07/30/2008EP1949913A1 Immunostimulatory combination for the prophylactics and treatment of hepatitis c
07/30/2008EP1949908A1 Combined use of derivatives of GLP-1 analogs and PPAR ligands
07/30/2008EP1948828A2 Multimeric biosensors and methods of using the same
07/30/2008EP1948827A2 C-kit oncogene mutations in melanoma
07/30/2008EP1948807A2 Plants having improved growth characteristics and a method for making the same
07/30/2008EP1948804A2 Methods of making modular fusion protein expression products
07/30/2008EP1948802A1 Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response
07/30/2008EP1948799A1 Use of bacteriocins for promoting plant growth and disease resistance
07/30/2008EP1948798A1 Anti-alpha2 integrin antibodies and their uses
07/30/2008EP1948793A2 Method for conversion of uric acid to allantoin and related enzymes
07/30/2008EP1948692A2 Rankl antibody-pth/pthrp chimeric molecules
07/30/2008EP1948689A1 High activity growth factor mutants
07/30/2008EP1948688A2 Compositions of and methods of using stabilized psma dimers
07/30/2008EP1948687A2 A polypeptide complex of trpm8 and calmodulin and its uses thereof
07/30/2008EP1948685A1 Mu-conotoxin peptides and use thereof as a local anesthetic
07/30/2008EP1948684A1 Production of recombinant collagen like proteins
07/30/2008EP1948683A1 Emp4 gene
07/30/2008EP1948682A1 Plants having improved growth characteristics and a method for making the same
07/30/2008EP1948680A2 Methods and compounds for lymphoma cell detection and isolation
07/30/2008EP1948679A1 Method for preparing recombinant peptide from spider venom and analgesic composition containing the peptide
07/30/2008EP1948246A2 Stem cell factor therapy for tissue injury